CRISPR Therapeutics and Intellia face 2025 volatility, but CRSP’s strong cash and launches make it more attractive than NTLA.

Columnist Robert Behre writes that it's a mystery why Charleston's grandest public building, the U.S. Customhouse, is also ...

Vislink Technologies, Inc. ("Vislink” or the "Company”) (OTCQB: VISL), a global technology leader in the capture, delivery, ...